Bellerophon Therapeutics (NASDAQ:BLPH) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a research report sent to investors on Friday. The firm issued a hold rating on the biotechnology company’s stock.

Bellerophon Therapeutics Price Performance

NASDAQ:BLPH opened at $0.04 on Friday. Bellerophon Therapeutics has a 52-week low of $0.03 and a 52-week high of $0.46. The firm has a market cap of $428,050.00, a P/E ratio of -0.04 and a beta of 0.70. The business’s 50-day moving average price is $0.04 and its 200 day moving average price is $0.05.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.